TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05607706

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure to maternal odor
Description: Exposure to maternal odor; the shirt worn by the mother is put in the baby's incubator, kangaroo care; mother lays her baby naked between her breasts

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure to maternal odor
Description: Exposure to maternal odor; the shirt worn by the mother is put in the baby's incubator, kangaroo care; mother lays her baby naked between her breasts
Study: NCT05486585

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet delivered cognitive behavioural therapy for functional gastrointestinal disorders
Description: The offered treatment will be the Danish versions of the Swedish i-CBT programs for children. The child i-CBT program consists of 10 modules for the child and 10 for parents. The adolescent i-CBT program consists of 10 modules for the adolescent and 5 modules for the parents. Child and adolescents modules compose of exposure exercises for symptoms, behavioural analyses and affect labelling and are adjusted for the specific age group. Parent modules aim at supporting parents in helping their child to engage in the challenging exposure exercises. The family needs to select one parent to participate in the parent program. The participants will be expected to use approximately 4 hours per week. The programs will be delivered over ten weeks, and therapist support will be provided on a weekly basis.
Study: NCT03879304

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multimodal physiotherapy program with RV
Description: Physiotherapy Programm includes: respiratory physiotherapy, stretching, resistance training, aerobic training and adaptation and training with virtual reality glasses and relaxation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional physiotherapy program
Description: Multimodal physiotherapy Programm includes: traditional physiotherapy, stretching, massage.
Study: NCT06106919

Intervention type: OTHER
Intervention: surveys (Fertiqol and WHOQOL-BREF)
Description: surveys (Fertiqol and WHOQOL-BREF)

Intervention type: OTHER
Intervention: surveys (Fertiqol and WHOQOL-BREF)
Description: surveys (Fertiqol and WHOQOL-BREF)

Intervention type: OTHER
Intervention: surveys (Fertiqol and WHOQOL-BREF)
Description: surveys (Fertiqol and WHOQOL-BREF)
Study: NCT06530888

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Process-based Cognitive Behavioral Therapy (PBT)
Description: Intervention planning based on the use of EMA data, feedback of dynamic network analysis and matching of interventions to central nodes of the network.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine practice (r-PT)
Description: Intervention planning as usual.
Study: NCT05320393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PrabotulinumtoxinA-Xvfs
Description: One treatment of 40 units

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OnabotulinumtoxinA
Description: One treatment of 20 units

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PrabotulinumtoxinA-Xvfs
Description: One treatment of 20 units
Study: NCT05066308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD
Description: Epidiolex, an agent within the anti-epileptic drug class, will be used. Epidiolex, Greenwich Biosciences Inc.'s CBD formulation, is a 100 mg/mL purified oral solution, dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring. The drug is formulated from extracts prepared from Cannabis sativa L. plants that have a defined chemical profile and contain consistent levels of CBD as the principal phytocannabinoid. Extracts from these plants are processed to yield pure (\>95%) CBD that typically contains less than 0.5% (w/w) THC. Cannabidiol is the active ingredient in Epidiolex; inactive ingredients include dehydrated alcohol, sesame seed oil, strawberry flavor, and sucralose. Of note, CBD has no psychoactive properties.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo CBD will be identical to the active CBD, a 100 mg/mL purified oral solution, dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring, but with no CBD.
Study: NCT05397054

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: - Education: Education about risk of high sodium intake, type of sodium, nutrition ingredients

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reformulation
Description: - Reformulation: Dietary recommendation in low sodium intake

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Environmental change
Description: - Environmental change: Encourage about low sodium intake in community

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Salt meter
Description: - Used salt meter: at least 3 times/wk

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: standard treatment
Study: NCT05383547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Dexamethasone 10mg+ bortezomib (1.3mg /m2 IV) was administered at D1,D4,D8,D11, one month for 1 cycle, for 2 cycles.
Study: NCT05872711

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet
Description: In order to maintain equal intensity of treatment, each patient will get a cooking workshop and received a personalized diet regime at baseline, based on the randomly assigned diet. Format and quality of the materials are similar.~All diet plans are individualized and matched for energy intake personally . Participants will meet individually with the dietitian for diet instruction and support at week 1,2,4,7,10,12 and thereafter at 24 weeks for a total of seven frontal meetings. Twice during the first 12 weeks the dietician will conduct 10-15-minute motivational telephone calls with all the participants.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low carbohydrate diet
Description: In order to maintain equal intensity of treatment, each patient will get a cooking workshop and received a personalized diet regime at baseline, based on the randomly assigned diet. Format and quality of the materials are similar.~All diet plans are individualized and matched for energy intake personally . Participants will meet individually with the dietitian for diet instruction and support at week 1,2,4,7,10,12 and thereafter at 24 weeks for a total of seven frontal meetings. Twice during the first 12 weeks the dietician will conduct 10-15-minute motivational telephone calls with all the participants.
Study: NCT05469139

Intervention type: DIAGNOSTIC_TEST
Intervention: Portable MRI acquisition
Description: Patients on ECMO will undergo a portable MRI of the brain
Study: NCT04397458

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: 0.9% saline on each side

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 0.25% bupivacaine (50mg) on each side

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 3mg preservative-free dexamethasone on each side
Study: NCT04878692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Application of Onco-Rash cream
Description: The cream Onco-Rash will be administered topically. The patient will be asked to apply the cream twice a day in the morning and evening for 6 weeks to clean, dry skin on selected target areas of the body, namely: the face, the front of the neck, the front of the chest, the back of the neck and the back of the chest. The product penetrates by gentle massage.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Application of Onco-Neutre cream
Description: The cream Onco-Neutre will be administered topically. The patient will be asked to apply the cream twice a day in the morning and evening for 6 weeks to clean, dry skin on selected target areas of the body, namely: the face, the front of the neck, the front of the chest, the back of the neck and the back of the chest. The product penetrates by gentle massage.
Study: NCT05023525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK31858, tablet
Description: Starting dose in single ascending dose: 5 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, tablet
Description: Matching placebo
Study: NCT06208605

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Network Informed Personalized Treatment
Description: Idiographic network analysis is used to determine individuals' top central eating disorder symptoms. Participants then receive modules to address these specific symptoms.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Cognitive Behavioral Therapy for Eating Disorders
Description: Manualized CBT-E (Fairburn 2008) including regular eating, self-monitoring, and CBT modules implemented flexibly.
Study: NCT04253951

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lung Ultrasound (LUS)-monitored feeding trial
Description: LUS-monitored (before and after) feeding trial (different consistencies might be tested in separate repeated trials according to clinical evaluation). A further LUS evaluation will be performed at a distance of 3 hours, before the next meal to check for resolution of after-meal abnormalities. All pulmonary fields will be explored according to semeiotics and previous literature.

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Lung Ultrasound (LUS)-monitored feeding trial
Description: LUS-monitored (before and after) feeding trial (different consistencies might be tested in separate repeated trials according to clinical evaluation). A further LUS evaluation will be performed at a distance of 3 hours, before the next meal to check for resolution of after-meal abnormalities. All pulmonary fields will be explored according to semeiotics and previous literature.
Study: NCT05539118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human interferon α1b
Description: Recombinant human interferon α1b is a protein with potent antiviral, antiproliferative and immunomodulatory properties.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab is a recombinant, humanized programmed death receptor (PD-1) monoclonal antibody that binds to PD- and prevents binding of PD-1 with programed death ligands 1 (PD-L1) and PD-L2. It can function to activate cytotoxic T lymphocytes and inhibit tumor growth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride
Description: Anlotinib hydrochloride is a novel oral tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR) and c-kit.
Study: NCT05020392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTK inhibitor+ Fludarabine-based chemotherapy + CAR-T-CD19 Cells
Description: BTK inhibitor from enrollment to more than 90 days after CAR-T-CD19 infusion. Fludarabine-based lymphodepletion chemotherapy was followed by CART19 infusion at a dose of 1x10\^6/kg on day 0 and day 1 respectively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine-based chemotherapy + CAR-T-CD19 Cells
Description: Fludarabine-based lymphodepletion chemotherapy was followed by CART19 infusion at a dose of 1x10\^6/kg on day 0 and day 1 respectively.
Study: NCT05333276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3602 Capsule + AK105 Injection
Description: TQB3602 is a kind of proteasome inhibitor, AK105 is an anti-PD-1 antibody.
Study: NCT05576701

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Laughter Therapy
Description: In this study, laughter therapy was applied to the experimental group three times a week (on Mondays, Wednesdays, and Fridays) for a total of 12 sessions. Each session started with other patients in the HD unit while the patient was receiving HD treatment (1 hour after HD started) and lasted 30-45 minutes. The number of patients who will take part in each laughter session is based on the number of patients attending that session in the hemodialysis unit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The patients in the control group, on the other hand, did not undergo any intervention other than their routine treatment and care. Laughter therapy was applied for four weeks to HD patients in the control group who wanted the results of the research.
Study: NCT06303531

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Fumarate
Description: Ferrous Fumarate - 300 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Polysaccharide Iron
Description: Polysaccharide Iron - 150 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Ascorbate
Description: Ferrous Ascorbate - 100 mg
Study: NCT04825340

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Nasal Spray Lyophilized Live Attenuated Influenza Vaccine
Description: 0.2 ml/vial, 0.2ml/dose/per person

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nasal Spray Lyophilized Live Attenuated Influenza Vaccine
Description: 0.2 ml/vial, 0.2ml/dose/per person
Study: NCT06016166

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eye mask
Description: The 3D eye mask with the ability to adjust for different faces and eliminate light
Study: NCT05095948

Intervention type: PROCEDURE
Intervention: Discussion
Description: Undergo audio recording of clinic conversations

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Review of medical records
Study: NCT04977778

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fatty Acids Compounds (F.A.G.) Mouthwash
Description: Fatty Acids Compounds (F.A.G.) Mouthwash

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stannous Fluoride (SF) Mouthwash
Description: Stannous Fluoride (SF) Mouthwash
Study: NCT06399458

Intervention type: DIAGNOSTIC_TEST
Intervention: For hypermobility; Beighton score and Brighton revised 1998 Criteria
Description: Beighton score and Brighton revised 1998 Criteria

Intervention type: DIAGNOSTIC_TEST
Intervention: For hypermobility; Beighton score and Brighton revised 1998 Criteria
Description: Beighton score and Brighton revised 1998 Criteria
Study: NCT05095948

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT05192213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Patients will be allocated in a 1: 1 ratio to the treatment group, receiving intravenous Vitamin C (1.5 g every 6 hours), Thiamine (200 mg every 12 hours) and Hydrocortisone (50 mg every 6 hours) for 7 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive 2 placebos (every 6 hours and every 12 hours) + Hydrocortisone (50 mg every 6 hours) for 7 days.
Study: NCT05713539

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metal block
Description: Small sheet of copper will be used when cooled to the designated temperature
Study: NCT05002387

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NanoScope™ Operative Arthroscopy (Arthrex, Inc)
Description: Needle arthroscopy will be performed in the operating room to visual the medial, lateral, and patellofemoral compartments prior to undergoing either unicompartmental or total knee arthroplasty
Study: NCT06220019

Intervention type: DRUG
Intervention: TCM
Description: We will perform subgroup analyses based on specific TCM interventions (such as Chinese patent medicines or external therapies) and the duration of TCM treatment (for example, comparing patients who receive continuous oral Chinese patent medicine for two months or more each year with those who do not). These analyses will assess the efficacy and safety of TCM.
Study: NCT05656781

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief Intervention and Contact (BIC) based on Word Health Organization (WHO)
Description: Intervention based on: Clinical WHO - SUICIDE PREVENTION DOCUMENT MULTISITE INTERVENTION STUDY ON SUICIDAL BEHAVIOURS - SUPRE-MISS: PROTOCOL OF SUPRE-MISS. Brief Intervention and Contact with participants using follow up questions about mood or any suicide attempts.
Study: NCT06506929

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task specific physical therapy
Description: Physical Therapy based specifically on tasks that the participant os having difficulty with
Study: NCT04425395

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cold pressor task (CPT)
Description: The cold pressor test is among the most common and established methods for studying human reactions to pain and pain tolerance. Participants submerge a hand in cold water (approx. 5°C) and are asked to keep their hand submerged for as long as can (until the sensation is intolerable), up to a maximum of 5 min. The procedure is safe because the hand is removed before adverse effects can occur. The participant will be given a break of 5 min in between trials, and will interchange hands between trials. During this break hand may to be place in warm water (25-35°C) for up to 4 min to normalise hand temperature, which will be measured before and after each trial using a digital thermometer held firmly in the palm of the hand.~Each participant will complete no more than three trials (conditions) in a randomised order.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acoustic Recordings
Description: During the experiment, the vocalizations produced will be systematically recorded for each participant and an analysis of the acoustic structure of these vocalizations will be carried out.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Index measurement NOL™
Description: Four sensors placed non-invasively on one finger. of the participants will be able to calculate a dozen physiological parameters converts in real time into a pain index called NOL (for Nociception Level Index).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Video pupillometry
Description: This technique is based on the observation of the dilatation of the pupil during the perception of a nociceptive stimulus in test persons.
Study: NCT05103215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine HCl 2%
Description: Intravenous injection of 1.5 mg/kg lidocaine at induction of anesthesia and continuous infusion of 1.5 mg/kg/h (ideal body weight) through the maintenance period to one hour after operation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Intravenous injection of 1.5 mg/kg normal saline at induction of anesthesia and continuous infusion of 1.5 mg/kg/h (ideal body weight) through the maintenance period to one hour after operation.
Study: NCT05934175

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive treatment with prolonged exposure
Description: Intensive treatment with prolonged exposure

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weekly delivered prolonged exposure
Description: Weekly delivered prolonged exposure sessions for 15 weeks
Study: NCT05870761

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo MRI/CT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI/CT
Study: NCT06267066

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone Valerate 0.1% Cream
Description: Moderate potency

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone Valerate 0.1% Cream
Description: Moderate potency

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SmartXide® fractional carbon dioxide laser
Description: Ablative

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SmartXide® fractional carbon dioxide laser
Description: Ablative

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaseline Topical Product
Description: Emollient

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaseline Topical Product
Description: Emollient

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaseline Topical Product
Description: Emollient
Study: NCT05018026

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutri-Grade labels
Description: All beverage products in the arm are displayed with the Nutri-Grade label. This label was proposed by the Ministry of Health in Singapore to be implemented at the end of 2021. It will apply to all pre-packaged non-alcoholic beverages sold in Singapore. It will have four color-coded grades wherein Grade A, corresponding to the lowest sugar and saturated fat thresholds, will be in green and Grade D, corresponding to the highest sugar and saturated fat thresholds, will be in red.
Study: NCT06543680

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dental restoration
Description: Each patient will randomly receive one cervical restoration with one of the tested restorative systems

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dental restoration
Description: Each patient will randomly receive one cervical restoration with one of the tested restorative systems

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dental restoration
Description: Each patient will randomly receive one cervical restoration with one of the tested restorative systems
Study: NCT05792527

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-carnitine
Description: One 500 mg tablet twice daily after meals
Study: NCT06234215

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: functional electrical stimulation
Description: electrical stimulation during function
Study: NCT05870761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Given PO
Study: NCT05172232

Intervention type: DIAGNOSTIC_TEST
Intervention: Dermalyzer
Description: To evaluate the diagnostic accuracy of the Dermalyzer device to detect melanoma among cutaneos skin lesions by dermoscopy.
Study: NCT03542695

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper Cu-64-DOTA-alendronate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic Study
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT06234215

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: functional task training
Description: functional exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: functional task training
Description: functional exercise
Study: NCT04878952

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Garmin Vivofit Activity Tracker
Description: Activity tracker that is worn on the wrist.